Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study - Top-Institutions - MDSpire

Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study

  • By

  • Mengwei Feng

  • Yunjie Wu

  • Chaoqing Xie

  • Jingxian Xing

  • Deguang Wang

  • Xue Liang

  • Juan Liu

  • Hui Gao

  • Tao Geng

  • July 15, 2026

Share

Top Institutions in Cardiology

Brief introduction explaining scope and methodology.

  • #1

    Cangzhou Central Hospital of Hebei Medical University
    Cangzhou Central Hospital of Hebei Medical University

    Cangzhou, Hebei

    Key Differentiators

    • Cardiology

  • #2

    Instituto Nacional de Cardiología “Ignacio Chávez”
    Instituto Nacional de Cardiología “Ignacio Chávez”

    Mexico City, Mexico

    Key Differentiators

    • Cardiology

Original Source(s)

Rivaroxaban plus antiplatelet therapy for coronary artery ectasia: 36-month outcomes and risk prediction from a retrospective cohort study

  • by Mengwei Feng, Yunjie Wu, Chaoqing Xie, Jingxian Xing, Deguang Wang, Xue Liang, Juan Liu, Hui Gao, Tao Geng

  • July 15, 2026

Related Content

Determinants of exercise capacity in heart failure with preserved ejection fraction: central hemodynamics, ventilatory efficiency, and peripheral muscle oxygen utilization and function

Early predictive value of prediction models for mortality after transcatheter aortic valve replacement: a systematic review and meta-analysis

Insomnia severity modifies diary-based sleep-continuity and sleep-initiation associations with next-day daytime HRV in a real-world wearable dataset